Subscriber access provided by University of Sussex Library
Article
High Resolution Capillary Isoelectric Focusing Mass Spectrometry Analysis of Peptides, Proteins and Monoclonal Antibodies with a Flow-Through Microvial Interface Lingyu Wang, Tao Bo, Zheng-xiang Zhang, Guanbo Wang, Wenjun Tong, and David D. Y. Chen Anal. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.analchem.8b02175 • Publication Date (Web): 11 Jul 2018 Downloaded from http://pubs.acs.org on July 13, 2018
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
1
High Resolution Capillary Isoelectric Focusing Mass Spectrometry Analysis of Peptides,
2
Proteins and Monoclonal Antibodies with a Flow-Through Microvial Interface
3 4
Lingyu Wang1,2, Tao Bo3, Zhengxiang Zhang3, Guanbo Wang1, Wenjun Tong1*, and David Da
5
Yong Chen1,2*
6 7
1. College of Chemistry and Materials Science, Nanjing Normal University, Nanjing, China 210023
8
2. Department of Chemistry, University of British Columbia, Vancouver, BC, Canada V6T 1Z1
9
3. Thermo Fisher Scientific, 7th Floor, Building F, Tower West, Yonghe Plaza, No. 28 Andingmen
10
Street East, Beijing, China 100007
11 12 13 14 15 16 17 18 19 20 21 22
* To whom correspondence should be addressed:
23
Wenjun Tong, Tel.: +8625 8589 1319, Email:
[email protected] 24
David Da Yong Chen, Tel: +1 604 822 0878, Email:
[email protected] 1
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
25 26
Abstract
27
Capillary isoelectric focusing directly coupled to high resolution mass spectrometry (cIEF−MS)
28
provides information on amphoteric molecules, including isoelectric point and accurate mass, which
29
enables structural interrogation of biopolymer pI variants. The coupling of cIEF with MS was
30
facilitated by a flow-through microvial interface, made by stainless steel with high chemical
31
resistance and mechanical robustness. Two on-column electrolyte configurations of cIEF−MS were
32
demonstrated using peptide and protein pI markers. The pI resolution was 0.02 pH unit in the pH
33
range of 5.5 to 7.0, with no anti-convective reagent (glycerol) added. High resolution Orbitrap
34
detector provides mass spectra for mid-sized proteins (< 30 kDa), enabling deconvolution with high
35
accuracy for IEF-focused low abundance species. Charge heterogeneity of therapeutic monoclonal
36
antibodies (mAb) is one of the most important attributes in the biopharmaceutical industry, and it is
37
routinely monitored by IEF and fractionation based methods. As a proof of concept, the commercial
38
formulation of infliximab was directly analyzed using cIEF−MS for separation and online
39
identification of mAb charge variants. The main intact antibody species along with two basic and
40
one acidic variants were observed, and their accurate molecular weights (Mw) recorded by MS
41
detector readily revealed the structural differences of these variants. Variants with 0.1 unit in pI
42
difference and 1 Dalton difference in molecular weight were readily resolved. The deconvoluted
43
intact Mw values showed ppm level accuracy compared to theoretical predictions.
44
2
ACS Paragon Plus Environment
Page 2 of 24
Page 3 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
45
Analytical Chemistry
1. Introduction
46 47
Capillary electrophoresis (CE) utilizes electric field to drive the separation of analytes based on their
48
electrophoretic mobilities, which are proportional to their charge-to-size ratio.1 With the same
49
instrument, capillary isoelectric focusing (cIEF) can be performed to separate amphoteric analytes
50
(e.g., peptides and proteins) based on their different isoelectric points (pI),2 and it is currently the
51
second most frequently performed working mode to capillary zone electrophoresis (CZE).3 Capillary
52
electrophoresis mass spectrometry (CE–MS) is a complementary technology to the widely used
53
liquid chromatography mass spectrometry (LC–MS) because of its low sample consumption, high
54
resolving power, and distinct separation mechanism which provides more information on more
55
hydrophilic molecules.4-7 In addition, high resolution MS provides additional structural interrogation
56
capability using accurate mass and tandem MS functionality.8 As the prime example of high
57
resolution full mass scanner, Orbitrap mass analyzers offer adjustable superb resolution with high
58
stability in mass accuracy.9
59 60
Because of the requirement for stable operations is different for liquid phase CE and gas phase
61
electrospray ionization (ESI), the online coupling of CE–MS is not as straightforward as that of LC–
62
MS. Since the first demonstration of CE-MS in 1987, which employed a coaxial configuration with a
63
sheath liquid, there has been 3-decades of effort to improve the robustness and sensitivity of the
64
hyphenated instrument.4,5,7 Some recent work has shown that the limit of detection (LOD) of
65
approximately 600 peptide molecules, which is close to the LOD of laser-induced fluorescence, can
66
be achieved.10,11 A sheathless design with an etched porous tip directly served as the ESI sprayers
67
has also shown remarkable sensitivity and have found many applications in biopharmaceutical
68
research.12,13 Microfluidic CE–MS has also been demonstrated, and has been used for intact antibody
69
analysis.14 We developed a beveled-tip non-symmetrical emitter with a flow-through microvial
3
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
70
interface, which utilized a stainless steel needle as the ESI sprayer.15 The hydrodynamic flow pattern
71
inside the microvial retained peak shape characteristics of eluted analytes while the beveled emitter
72
geometry maintains stable electrospray over a wide flowrate range.16,17 Several CE–MS systems to
73
online couple cIEF–MS have been demonstrated since 1995.18,19 The flow-through microvial
74
interface has been used for cIEF–MS analysis of proteins, and the buffer composition including the
75
amount of glycerol and ampholyte were optimized.20 Similar conditions were used by another group
76
recently to demonstrate that monoclonal antibodies can be characterized by cIEF-MS using a pulled
77
tip glass sprayer,21 which was also used for cIEF tandem MS analysis of digested protein lysates and
78
intact proteins has also been reported.22-24
79 80
The combination of cIEF separation and ESI-MS detection is analogous to 2-dimensional gel
81
electrophoresis (2D GE).18 Meanwhile, it eliminates the needs for hands-on operations, and has
82
accurate mass measurement stemming from state-of-the-art mass spectrometers.19 Earlier works
83
showed that the catholyte can be manually changed to acidic CE–MS sheath liquid, and volatile
84
acids and bases (e.g., acetic acid, formic acid, ammonium hydroxide, etc.) can be used instead of
85
inorganic ones for MS compatibility.18,25-27 The online coupling of cIEF to Fourier transform ion
86
cyclotron resonance (FT-ICR) MS demonstrated for the first time the benefit of the highly accurate
87
isotopic resolving power in protein analysis.25 Later, a sandwich configuration with the analyte
88
segment sandwiched by anolyte and catholyte was developed for full automation.20,28,29 Conventional
89
IEF additives (e.g., methyl cellulose) minimize the convection/diffusion-related band broadening to
90
maintain IEF resolution during mobilization of focused bands to the MS detector, but common anti-
91
convective reagents inevitably diminished ionization efficiency, and introduced unacceptable MS
92
contamination.19 Glycerol was found to be suitable as it can maintain the IEF resolution and is
93
largely MS compatible.28
94
4
ACS Paragon Plus Environment
Page 4 of 24
Page 5 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
95
Therapeutic monoclonal antibodies (mAb) that are proven effective in the treatment of malignant
96
cancers and chronic autoimmune diseases significantly benefit patients.30,31 Unlike synthesis-based
97
production of small molecule drugs, recombinant mAbs are expressed by biologically engineered
98
hybridoma cell lines in vitro.32 Stemming from the complex nature of biologics production and
99
purification, various in vivo and in vitro modifications result in the existence of micro-heterogeneity,
100
including N-terminal cyclization, C-terminal lysing clipping, N-glycosylation, glycation, oxidation
101
of methionine/tryptophan, asparagine degradation and cysteine-related post translational
102
modifications (PTM).33 It gives rise to concerns about diminished potency of antigen binding and
103
increased risk of immunogenicity.33,34 Even though the modifications seem very small compared to
104
the tremendous size of intact mAbs, most of them cause observable shifts on isoelectric points (pI)
105
of typically 0.1 to 0.2 pH unit.35 To guarantee the safety and reliability of therapeutic biologics,
106
analysts in industry often use cIEF with point or whole column optical detection for charge
107
heterogeneity characterization.36 cIEF is the current gold standard for mAb characterization, but the
108
absorbance traces provide no structural information, requiring laborious fractionation for further
109
structural interrogation of separated charge variants. cIEF–MS analysis can readily fulfill the needs
110
of online micro variant identification.
111 112
In this report, the latest progress of cIEF−MS analysis facilitated by the flow-through microvial
113
interface is described. Peptide pI markers were used to demonstrate that resolution of 0.02 pH unit
114
with chemical mobilization can be achieved without the use of glycerol, and 0.08 pH unit with
115
glycerol added using combined hydrodynamic and chemical mobilization. With spectrum
116
deconvolution, the isotopically resolved charge envelopes of protein pI markers can be obtained.
117
Infliximab, a therapeutic mAb, was directly subjected to the cIEF–MS analysis without desalting.
118
With the Orbitrap MS, four mAb charge variants were successfully profiled on the total ion
5
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
119
chromatograph (TIC) and infliximab variant structures of 13 unique Mw values were identified with
120
ppm-level mass accuracy.
121 122
2. Experimental
123 124
2.1. Chemical and materials
125 126
Deionized water (18.0 MΩ/cm) was collected from a Milli-Q ultrapure water purification system
127
(Millipore, Bedford, MA, USA) and utilized for the preparation of all aqueous solution. Methanol
128
(LC-MS grade), formic acid (FA, 99%, ACS grade), acetic acid (AcOH, 99%, ACS grade),
129
ammonium hydroxide (NH3, ACS grade, 25%, w/w), sodium hydroxide (NaOH, ACS grade),
130
concentrated hydrogen chloride solution (HCl, ACS grade) arginine (Arg, >99% ACS grade),
131
iminodiacetic acid (IDA, >99%), hydroxyl propyl cellulose (HPC, averaged Mw 80,000), and
132
glycerol (ACS grade) were all purchased from Sigma Aldrich (Nepean, ON, Canada). Two brands of
133
carrier ampholyte (CA) were used in this work: Fluka (pH 3~10, 40% w/w in water, purchased from
134
Sigma Aldrich) and ampholyte (pH 3~10, 0.36 meq/mL·pH, GE Healthcare, Chicago, IL, USA).
135
Bare silica capillaries (50 µm i.d.) were purchased from Polymicro Technologies (Molex, IL, USA).
136
Agilent Technologies (Beijing, P. R. China) kindly provided the polyvinyl alcohol (PVA) coated
137
capillaries (50 µm i.d.) in this work. The IEF capillaries were neutrally coated with hydrophilic
138
polymers (PVA or HPC) to suppress electro-osmotic flow (EOF). The HPC coating protocol was
139
slightly modified from what was reported by Shen.37
140 141
Peptide pI marker kit was purchased from SCIEX Separations (Brea, CA, USA) containing five
142
synthetic peptide markers (5.0 mg/mL in water) with pI values of 10.0, 9.5, 7.0, 5.5, and 4.1. The
143
protein pI markers purchased from Sigma Aldrich (Shanghai, China) were ribonuclease A from
6
ACS Paragon Plus Environment
Page 6 of 24
Page 7 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
144
bovine pancreas (RNase-A, pI 9.6), myoglobin from equine heart (Myo I pI 6.8, Myo II pI 7.0),
145
carbonic anhydrase I human (HCA I, pI 6.5), bovine carbonic anhydrase (BCA, pI 6.1) and β-
146
lactoglobulin (Beta-lac, pI 5.1). Another protein mixture commercialized as a slab gel IEF reference
147
was purchased from Bio-Rad Laboratories (Hercules, CA, USA), consisting of cytochrome C (Cyt,
148
pI 9.6), human hemoglobin (HH, type C pI 7.5, type A pI 7.1), equine myoglobin (Myo I pI 7.0, Myo
149
II pI 6.8), human carbonic anhydrase (HCA, pI 6.5), Bovine carbonic anhydrase (BCA, pI 6.0) and
150
β-lactoglobulin (Beta-lac, pI 5.1). The prescription drug infliximab (Remicade, 100 mg/vial
151
formulation) was kindly provided by Agilent Technologies (Beijing).
152 153 154
2.2. Instrumentation
155
Two CE−MS platforms were used for cIEF−MS experiments. The first set used an Agilent 7100 CE
156
system and an Agilent 6530 QTOF mass spectrometers, which was a Quadrupole Time of Flight MS
157
(Q-TOF MS). The chemical modifier solution was delivered by an additional Agilent 1260 NanoLC
158
pump. The flow-through microvial interface was installed on a home-made 3D-adjustable stage. The
159
second platform consists of a Sciex PA800+ CE system and a Thermo Scientific Orbitrap Fusion
160
Lumos mass spectrometer which is a tribrid platform of quadrupole, Orbitrap and linear ion trap. The
161
modifier was delivered by a syringe pump. The flow-through microvial interface was directly fixed
162
on the Thermo Scientific Nanospray Flex Ion Source. All systems realized fully automation, with
163
exception of cIEF-MS using the second configuration (vide infra). The protein concentration was
164
measured by a Thermo NanoDrop 2000 spectrophotometer at 280 nm or was based on analytical
165
balance. The charge envelope deconvolution relied on the algorithm of Thermo Scientific Protein
166
Deconvolution 4.0.
167 168
2.3. cIEF−MS configurations
169
7
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
170 171
Figure 1. (A) The first cIEF−MS configuration for protein and mAb analyses. The separation
172
capillary was sequentially filled with anolyte, sample and catholyte segments, forming a sandwich
173
structure. The flow-through microvial inside the ESI emitter was linked to a nanoLC or a syringe
174
pump for the chemical modifier delivery. (B) The focusing stage for the second configuration. The
175
capillary was filled with the ampholytes–analyte mixture. The CE inlet vial contained anolyte while
176
the flow-through microvial was filled by the basic catholyte. (C) The mobilization stage for the
177
second configuration. The pressure on the CE inlet and the migration of formate ions towards the
178
positive electrode initialized mobilization.
179 180
Two cIEF−MS configuration were used, as illustrated in Figure 1. The first configuration is fully
181
automated by employing a sandwich structure to eliminate the catholyte–modifier exchange, as
182
depicted in Figure 1(A).28 Three segments including the catholyte, sample and anolyte were
183
sequentially injected into the capillary and the segment lengths were controlled empirically by 8
ACS Paragon Plus Environment
Page 8 of 24
Page 9 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
184
injection time. Because of the shorter sample length (e.g., 37 to 40 cm), the focusing can be
185
completed in 30 min. Upon completion of focusing, mobilization was commenced by starting the
186
chemical modifier infusion and slightly pressurizing the CE inlet reservoir. The second configuration
187
is described in Figure 1(B and C). In this configuration, the whole capillary was filled with the IEF
188
sample while the sprayer flow-through microvial was filled with the basic catholyte by the syringe
189
pump. During the focusing step as illustrated by Figure 1(B), the catholyte was slowly pumped to
190
refresh the microvial which aims at washing away the electrolysis by-products. After the focusing
191
current was stabilized at a low value, the analyte mobilization was initialized by replacing catholyte
192
with the acidic chemical modifier composed of formic acid, methanol and water.
193 194
Capillary clean-up between the runs was crucial to the reproducibility and it was conducted prior to
195
and right after the cIEF–MS analysis. The rinsing procedure includes a mild water rinse and a 3.0 M
196
urea rinse. Acetic acid and ammonium hydroxide were utilized for MS compatibility. Glycerol (20%
197
v/v) used in place of the traditional anti-convention reagents, is mixed with anolyte, sample and
198
catholyte solutions.20,28,29 In the analysis of peptides which were less prone to surface adsorption,
199
glycerol was eliminated to maximize ESI efficiency.
200 201
2.4. cIEF−MS of peptide pI markers, protein pI markers and infliximab samples
202 203
Both methods were used for the analysis of peptide markers with the CE–Orbitrap MS platform with
204
HPC coated capillaries (1st configuration 80 cm and 2nd configuration 70 cm). The anolyte solution
205
was 1.0% (w/v) ammonia (0.59 M) in water, and the catholyte solution was 1.0% (v/v) acetic acid
206
(0.17 M) in water. The sample consisted of 2.0 mM IDA as the anolyte stabilizer, 2.5 mM arginine
207
as the catholyte stabilizer, as well as the Fluka ampholyte (2.5% v/v, stock solution) and five
208
synthetic peptide pI markers (pI 10.0, 9.5, 7.0, 5.5, 4.1) with the concentration of 50 µg/mL each. All
9
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
209
freshly prepared samples were vortexed and centrifuged by 12,000 rpm for 10 min at 10 ℃ prior to
210
analysis. The focusing stage utilized 30 kV (400 or 429 V/cm) for 45 min. During focusing, 4.5 kV
211
ESI voltage was turned off and 0.20 µL/min catholyte solution was pumped to refresh the flow-
212
through microvial. The chemical modifier solution was 0.50% (v/v) formic acid (0.13 M) in 80%
213
methanol (v/v) and its infusion (0.60 µL/min) was started right after the completion of focusing. The
214
anolyte-sample-catholyte length ratio for the sandwich configuration was 4:10:6, and its mobilization
215
utilized 25.5 kV plus 0.5 psi. There was 20% (v/v) glycerol added in the anolyte, sample and
216
catholyte segments using the sandwich configuration, but there was no glycerol for the other one.
217
The mobilization was based on 15 kV voltages only for the whole-column filling configuration. The
218
Orbitrap resolution was set at 60,000 and the ion transfer tube temperature was set as 300 ℃. In the
219
analyses using GE Healthcare ampholyte, the sample solution contained 1.0 mM IDA, 5.0 mM
220
arginine, and 2.5% (v/v) ampholyte stock solution. The focusing step was 30 kV for 35 min. All
221
other experimental details were the same as those when the Fluka ampholyte was used.
222 223
For the protein pI markers, the sandwich configuration using a 75.0 cm PVA coated capillary was
224
used on the CE–Q-TOF MS platform. Glycerol (20%, v/v) was added into the anolyte, sample and
225
catholyte. The anolyte and catholyte were 1.0% (v/v) acetic acid and 1.0% (w/v) ammonium
226
hydroxide. The sample contained 5.0 mM IDA, 5.0 mM arginine and 2.5% (v/v) Fluka ampholyte.
227
The protein markers were RNase-A (0.40 mg/mL), Myo (0.40 mg/mL), HCA I (0.40 mg/mL), BCA
228
(0.40 mg/mL) and Beta-lac (0.37 mg/mL). The length ratio of anolyte, sample and catholyte was
229
4:10:6. The focusing step utilized 30 kV (400 V/cm) for 25 min. The chemical modifier was 1.0 %
230
(v/v) formic acid in 80% methanol with a flowrate of 1.0 µL/min and it started 25 min after the
231
focusing was started. After another 5 min, a 50 mbar (0.73 psi) pressure was applied to accelerate the
232
mobilization. The ESI voltage, Fragmentor voltage and Skimmer voltage were 5.0 kV, 300 V and 65
233
V, respectively. The 300 ℃ drying gas flowrate was 4 L/min.
10
ACS Paragon Plus Environment
Page 10 of 24
Page 11 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
234 235
For protein analysis using the Orbitrap MS, 70.0 cm HPC coated capillaries were used for the
236
sandwich configuration and 55.0 cm HPC coated one for the other configuration. For the second
237
configuration, the catholyte solution was 1.0% (w/v) ammonia in 39% water and 60% methanol, and
238
the added methanol was to facilitate electrospray at the beginning of MS detection. The Bio-Rad
239
protein mixture concentration was about 0.10 mg/mL for each of the 6 proteins. The focusing step
240
was 30 kV for 30 to 45 min, depending on the sample segment length. The modifier was 2.0% (v/v)
241
formic acid (0.52 M) in 80% methanol with a flowrate of 0.60 µL/min. The chemical mobilization
242
was achieved by 25.5 kV. The ESI voltage, ion transfer tube temperature and Orbitrap resolution
243
were 4.5 kV, 350 ℃ and 300,000. Unless noted, all were same to the peptide analysis.
244 245
In the analyses of infliximab, the sandwich configuration and an 80 cm PVA coated capillaries were
246
utilized with the CE–Orbitrap MS system. In the 40-cm sample segment, the concentration of the
247
solid formulation was 0.50 mg/mL, and mAb concentration was measured to be 0.042 mg/mL. The
248
preservative salt and medicinal additive occupied 91.6% (w/w) of the infliximab formulation. Five
249
peptide pI markers of 10 µg/mL were then added to the solution. The 0.60 µL/min modifier pumping
250
was initialized right after the 30 min, 30 kV focusing step. After another 5 min, 0.5 psi (34 mbar)
251
was applied for combined hydrodynamic/chemical mobilization. The Orbitrap MS continuously
252
switched the m/z ranges between 100 to 1,500 for pI marker detection (Resolution 120,000) and
253
1,500 to 5,000 (Resolution 30,000) for mAb detection. The ESI voltage, ion transfer tube
254
temperature and in-source fragmentation were 4.5 kV, 350 ℃ and 100 V. All other parameters were
255
from the same as the cIEF–MS analysis of proteins.
256 257
3. Results and discussion
258
11
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
259
3.1. cIEF−MS analysis of peptide pI markers
260 261
To demonstrate the feasibility of our online CE–MS coupling strategies and to determine the pI
262
resolution of the proposed configurations, five synthetic peptide pI markers were subjected to cIEF–
263
MS analysis. It is a good practice to use these peptide for a test run to ensure the separation and
264
detection system is functional properly, especially because adding these markers in the real sample
265
has no adverse effect for the analysis. The second configuration involved the change from the
266
catholyte to the modifier in the flow-through microvial, because it replaced the distal end reservoir of
267
catholyte with microvial chamber inside the ESI emitter. The volume needed for the complete
268
solution exchange was measured to be 2.90 ± 0.15 µL (n = 6) and it brought a circa 3-min delay in
269
mobilization. Upon the completion of solution exchange by the acidic modifier, chemical
270
mobilization and electrospray ionization were initialized because the formate ions begun to replace
271
the hydroxide ions and titrate the pH gradient, and the methanol in the modifier facilitate the
272
desolvation of IEF eluents. The second coupling strategy demonstrated highest pI separation power
273
cIEF-MS can provide under optimal conditions. Because it used the whole separation capillary for
274
the sample segment, the volume injected was approximately three times higher than that of the
275
routine cIEF−UV protocol with sample segment of only 30 cm. Summarized in Table 1, pI
276
resolution as low as 0.021 pH unit can be achievable. Longer focusing and mobilization time is
277
needed, which were typically 45 min and 80 min using a 70 cm HPC coated capillary.
278
12
ACS Paragon Plus Environment
Page 12 of 24
Page 13 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
279 280
Figure 2. (A) cIEF−MS analysis of five peptide pI markers using the Fluka ampholyte. The three
281
insets were the zoomed in peaks for pI 5.5 marker in three consecutive experiments. (B) cIEF−MS
282
analysis of 5 peptide markers using the GE Healthcare ampholyte. The inset was the extracted ion
283
chromatogram (EIC) for ampholyte molecules with m/z 294.166. The pI values of ampholyte EIC
284
peaks were assigned according to the mobilization times of adjacent peptide markers.
285 286
Two different carrier ampholytes (pH 3 to 10) were utilized, and anti-convective reagent was not
287
needed for the cIEF–MS analysis of peptides. With Fluka ampholyte and chemical mobilization
288
voltage of 15 kV, very sharp EIC peaks of the pI 7.0, 5.5 and 4.1 markers were observed. As to the
289
sharpest pI 5.5 peptide marker, the smallest full width at half maximum (FWHM) was 2.7 seconds,
290
and 4.1 ± 0.8 seconds in average (n = 11 in 4 days). The pI 5.5 peak standard deviation was 0.21
291
seconds (0.0035 min), which is the highest reported cIEF-MS resolution to date. cIEF using
292
fluorescent detection has demonstrated sharper peaks with peak standard deviation of 0.13 s (0.0021
293
min) of the pI 6.5 marker.38 The peak symmetry in this work was 0.99 ± 0.35 (n = 11), demonstrating
294
that hydrodynamic flow patterns in the flow-through microvial contribute little to the peak distortion,
295
hence maintaining the IEF resolution with post-column detection. The pI resolution near the 13
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 24
296
migration time of pI 5.5 marker was as high as 0.021 pH, and in general 0.033 ± 0.007 pH (n = 11).39
297
To our best knowledge, this is the highest resolution achieved for online cIEF−MS analysis. As to
298
the pI 7.0 marker, the minimum FWHM was 4.1 seconds, and the average was 8.3 ± 3.1 seconds (n =
299
11). The smallest standard deviation was 0.24 seconds (0.0040 min). The corresponding pI resolution
300
was 0.024 pH, and on average 0.034 ± 0.009 pH. In the sandwich configuration with glycerol
301
addition, slightly lower pI resolution was observed using the combined hydrodynamic and chemical
302
mobilization. For pI 7.0 marker, even though the FWHMs were similar, the pI resolution of 0.08 pH
303
unit was 2.4 times lower. It’s been reported that discrete mAb variants were typically spaced out
304
with 0.2 pH intervals.35 With the system presented in this work, a 0.1 pH difference was sufficient to
305
be separated for the charge heterogeneity analysis of mAb therapeutics.
306 Table 1. Resolving power of the cIEF-MS method for peptides Ampholyte pI markers min. ∆pH ∆pH FWHM (s) 7.0 0.024 0.034 ± 0.009 8±3 Fluka1 5.5 0.021 0.033 ± 0.007 4.1 ± 0.8 9.5 0.055 0.07 ± 0.02 7.8 ± 0.3 2 GE 7.0 0.030 0.04 ± 0.01 3.7 ± 0.5 5.5 0.037 0.05 ± 0.02 3.7 ± 0.5 9.5 0.11 0.12 ± 0.03 13 ± 3 3 Fluka 7.0 0.06 0.08 ± 0.02 9±2 5.5 0.09 0.12 ± 0.03 9±1 1,2 3
n 11
3
3
70-cm sample plug, 2nd configuration, chemical mobilization
40-cm sample plug, 1st configuration, chemical mobilization and 0.5 psi pressure
307 308
As to the GE Healthcare ampholyte, it provided linear pH gradient with adequate pI resolution at
309
high pH regions. Sharp peaks of pI 10.0 and pI 9.5 markers were observed with slightly higher
310
amount of arginine spacer. The R2 between mobilization time and pI values was 0.99961 and 0.996 ±
311
0.004 in triplicate tests, respectively. By extracting ampholyte cations with m/z 294.166, nine peaks
312
appeared on the EIC profile as shown in the inset of Figure 2(B), which were structural isomers with
14
ACS Paragon Plus Environment
Page 15 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
313
pI differences. It is worth noting that the averaged m/z of GE ampholyte cations was approximately
314
400 while in the other types it was 500.
315 316
3.2. cIEF−MS analysis of protein pI markers
317 318
To minimize the convection-induced band broadening and prevent protein aggregation and
319
precipitation, solutions inside the separation capillary were mixed with 20% v/v glycerol for protein
320
analysis. The effect of amount of glycerol on protein separation has been studied previously.20,21
321
Because of the increased viscosity, a small pressure was applied to accelerate the analyte
322
mobilization.
323 324
With the CE–Q-TOF MS, one complete run of six protein markers can be finished within 90 min
325
with the sandwich configuration, including sample loading and IEF separation. The mobilization
326
stage needed an extra 50 mbar (0.73 psi) pressure to be completed within 30 min. As shown in
327
Figure 3(A), myoglobin I (pI 6.8) and myoglobin II (pI 7.0) were baseline separated, showing the
328
proper IEF resolution at the neutral region. Two minor myoglobin peaks were revealed, showing the
329
complexity of its charge variants. Two partially separated peaks for human carbonic anhydrase I
330
were detected, indicating two isoforms. The EICs were based on three to five most abundant signals
331
in the charge envelopes, and triplicate tests all have highly similar profiles. Compared with the
332
previous study of the identical marker cohort without the small pressure applied, the pI resolution
333
with pressure-assisted mobilization was well preserved at the basic and neutral regions, while the
334
peaks were somewhat broadened at the acidic region.20 The sandwich configuration is easy to
335
operate and completely automated. Therefore, it was used for the analysis of monoclonal antibodies
336
shown in the following section.
337
15
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
338 339
Figure 3. (A) The cIEF−MS analysis of a 6-protein mixture using the 1st configuration. The signal
340
intensity of RNase-A and Myo were multiplied by 10 and 0.5, respectively, for clarity of
341
presentation. (B) Analysis of a Bio-Rad protein marker mixture using the 2nd configuration on the
342
Orbitrap platform. The left inset demonstrated the isotopic pattern of Myo I + 13 H+, while the one
343
on the right was for Myo EIC. (C) Analysis of the Bio-Rad protein mixture with pure chemical
344
mobilization. The insets demonstrated the BCA EIC and the BCA + 25 H+ isotopic pattern. The
345
peaks with assigned numbers were listed in Table 2. Peaks of the same protein were labeled with the
346
same number across Panels A, B and C.
16
ACS Paragon Plus Environment
Page 16 of 24
Page 17 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
347 348
The Bio-Rad reference mixture contains six proteins and eight pI species, and it was slightly
349
different from the protein mixture analysis on the Q-TOF platform. The Bio-Rad sample was
350
subjected to IEF analysis using two configurations on the Orbitrap MS platform, as shown in Figure
351
3(B) and 3(C). The whole column filling configuration resulted in high pI resolution, while the
352
Orbitrap MS provided sensitive detection with up to 300,000 mass resolution. Synthetic peptide pI
353
markers were mixed with the proteins. By linear regression of the mobilization times to pI values of
354
peptide markers, the pI of other IEF peaks in Figure 3(B) was assigned and summarized in Table 2.
355
Two pI isoforms of β-lactoglobulin were observed, and the highly similar charge envelopes indicated
356
their charge variation with negligible mass shift, such as asparagine deamidation. In Figure 3, the
357
FWHM of BCA EICs were 22.0 seconds, 18.6 seconds and 7.0 seconds in Panel A, B and C,
358
respectively, and the sharpest BCA peak still had 15 points with the threshold set as 3% intensity of
359
peak maximum. The FWHM was larger in Figure 3(B) relative to Figure 3(C), suggesting that high
360
pI resolution required gentle chemical mobilization without the assisting pressure. With 300,000 MS
361
resolution, all proteins within 30,000 Da were isotopically resolved. Therefore, deconvoluted spectra
362
of all TIC peaks reliably revealed in-depth structural information by providing intact masses. Table 2
363
demonstrated the complexity of the Bio-Rad protein marker mixtures as revealed by the Orbitrap
364
detector, which is higher than that of the of 6-protein mixture analyzed on the Q-TOF platform. For
365
example, Peak 4 contained five intact masses with relative intensity > 5%. The right inset in Figure
366
3(B) was a summed EIC of myoglobin using the five highest isotopic peaks (∆ m/z < 0.5) of the
367
eight peaks of the charge envelope (+9 to +16), and it unambiguously showed a 3rd charge variant
368
with intensity of only 3.8% of the most abundant one. The Peak 2 and Peak 3 belonged to
369
hemoglobin A and C. Hemoglobin proteins dissociated into subunits (15,129 Da, 15,869 Da and
370
15,744 Da) during the ESI process in the acidic environment. We did not observe signals from intact
371
phycocyanin (Mw 232,000, pI 4.6) with the Orbitrap MS detector.
17
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 18 of 24
372
peak # 1 2
Table 2. Deconvolution results of cIEF-MS protein peaks name pI native mass (Da) and relative intensity Cyt 10.1 12361.08 90% 12347.04 10% HH-A/C
7.5
a a
3
Myo I
7.1
Myo II HCA
6.8 6.4
6
BCA
5.9
15128.72
b c
4 5
15128.73
44% 33%
15744.38
6%
16954.22 17569.88 28784.91
69% 9% 100%
d
15868.72 29% c
a
15744.38
16%
16954.24 29%
15869.66
20%
15128.73 12% 16977.23 5%
16995.28
10%
18301.7 18209.3
6% 6%
18279.69
57%
29028.43 43%
β-lac 5.8 18279.69 β-lac 4.7 18189.29 a, b, c, d The labels denote similar masses.
72% 47%
18604.05 18% 19237.65 40%
7 8
d
b
373 374
3.3. cIEF−MS analysis of infliximab, a monoclonal antibody pharmaceutical formulation
375 376
With the first configuration, we detected the charge envelopes of intact antibody in IEF eluents as
377
shown in Figure 4, demonstrating the feasibility of cIEF–MS analysis using the flow-through
378
microvial interface for analytes up to 150,000 Da. The infliximab sample with its formulation
379
containing salt and preservative additives was dissolved with deionized water and directly mixed
380
with carrier ampholyte and pI markers. The sample preparation step takes less than 20 min, including
381
the centrifugation step for particulate removal. The formulated sample contained 91.6% (w/w) salts
382
and additives, but their interference was alleviated by the desalting nature of IEF. Because half of the
383
separation capillary was assigned to the sample segment, 0.79 µL sample–ampholyte mixture (40 cm
384
× 50 µm) was injected, and the mAb consumption was only 33 ng for one complete analysis.
385 386
A combination of chemical and hydrodynamic mobilization (i.e., 25.5 kV and 0.50 psi) was applied
387
for analyte mobilization. The chemical modifier flowrate could be as low as 0.30 µL/min, but a 0.60
388
µL/min was routinely used to maintain the stable electrospray. During the focusing stage, the flow of
18
ACS Paragon Plus Environment
Page 19 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
389
chemical modifier brought no interference on the IEF separation. Many ionic species, such as Na+
390
from the preservative salts, could penetrate the catholyte segment and enter the interface microvial,
391
but they were washed out by the continuously flowing chemical modifier. Therefore, MS
392
contamination stemming from excipients was alleviated. By simultaneously monitoring the m/z
393
range between 100 to 1,200 and 1,500 to 5,000, both peptide markers and intact mAb was observed.
394
To maximize the sensitivity of mAb, the high mass range started at 1,500 was chosen to eliminate
395
the interference from carrier ampholyte with an averaged m/z of approximately 500, and one mAb
396
spectrum was composed of three microscans to enhance S/N.
397
398 399
Figure 4. (A) cIEF−MS TIC and five EICs of infliximab mixed with peptide pI markers on the CE–
400
Orbitrap MS platform. Five colored EICs belonged to the peptide pI markers. The markers traces
19
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 20 of 24
401
were magnified for clarity. (B) Raw EIC data of infliximab obtained with the m/z range of 3,000 to
402
5,000. The inset on the right was the averaged mass spectrum for the main IEF peak (#3). The
403
zoomed-in inset on the left demonstrated the details of the +39 peak cluster. (C) The deconvoluted
404
mass spectrum for the main peak.
405
Table 3. Deconvolution results and identified variant structures cIEF−MS peak
#1 K2
#2 K1
#3 K0 #4 Deamidation
glycoforms G0F/G0F-Man G0F/G0F G1F/G0F G1F/G1F G0F/G0F G1F/G0F G1F/G1F unknown G0F/G0F-Man G0F/G0F G1F/G0F G1F/G1F G2F/G1F unknown G1F/G0F
deconvoluted mass (Da) 148563.08 148768.77 148931.27 149094.39 148640.52 148800.44 148963.23 149103.47 148309.50 148512.86 148675.14 148837.39 148996.20 149059.89 148678.63
theoretical mass (Da) 148565.37 148768.56 148930.70 149092.84 148640.38 148802.52 148964.66 n. a. 148309.01 148512.20 148674.34 148836.48 148998.62 n. a. 148675.34
mass error (ppm) -15.4 1.4 3.8 10.4 0.9 -14.0 -9.6 n. a. 3.3 4.4 5.4 6.1 -16.2 n. a. 22.1
406 407
The maximum mAb signal (m/z 3376.35, 1.22E5) belonged to the +39 peak cluster, and it was only
408
0.014% of the highest co-eluted ampholyte signal (m/z 275.15, 8.72E8). It is the highly sensitive
409
Orbitrap MS that enabled the detection of intact mAb co-eluted with ESI-interfering carrier
410
ampholytes. In the m/z range of 3,000 to 5,000, no predominant carrier ampholyte signals were
411
observed and the mAb charge envelope was obtained with a clean baseline. Therefore, this wide EIC
412
can be considered the mAb TIC profile. At least four mAb charge variants were observed, as
413
demonstrated by Figure 4(B). The pI values of the resolved mAb peaks was assigned based on the
414
linear regression of peptide pI values to their mobilization times. In addition to the main peak, Peak 3
415
showing the intact mAb, and the two basic variants originating from C-terminal lysine clipping (∆m
20
ACS Paragon Plus Environment
Page 21 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Analytical Chemistry
416
128 Da), an acidic variant peak (Peak 4) appeared with a small mass shift on its deconvoluted
417
spectrum relative to the main peak.40 Asparagine deamidation was responsible for this variation as it
418
caused a +1 Da mass shift together with an acidic pI shift.41 Highly sensitive detection provided
419
detailed mass spectra and the following deconvoluted intact masses were in accordance with the
420
theoretical predictions, as summarized in Table 3. In total, 15 intact molecular weight values
421
originating from glycosylation heterogeneity and charge variation have been observed following
422
strict deconvolution settings (noise rejection 99% confidence, abundance threshold 3% and mass
423
tolerance 20 ppm), and 13 of them have been unambiguously correlated to the mAb microstructures
424
by theoretical prediction of Mw values. The averaged absolute mass error was only 8.7 ppm.
425 426
4. Conclusion
427 428
In this work, capillary isoelectric focusing was directly coupled to high-resolution mass
429
spectrometers with a stainless-steel flow-through microvial ESI interface. Two cIEF–MS
430
configurations had been demonstrated. The first one sequentially introduced the anolyte, sample and
431
catholyte segments into the neutrally coated capillary in a fully automated process, and the second
432
one used the whole capillary for IEF separation. Two instrumental platforms were used for the
433
evaluation of the two cIEF−MS configurations, including a CE–Q-TOF MS system and a high-
434
resolution CE–Orbitrap MS system. With the second configuration, the pI resolution reached 0.021
435
pH unit for peptide pI markers. As to protein markers such as BSA, the FWHM was as low as 7.0
436
seconds with isotopic pattern observed, showing the high resolving power delivered by both cIEF
437
and Orbitrap MS. Based on the aforementioned cIEF−MS methodology, we characterized an intact
438
monoclonal antibody sample, infliximab with its formulation. With only 30 nano grams of mAb
439
sample consumed in a single injection, four clearly defined TIC peaks demonstrated the
440
effectiveness of the IEF separation, while thirteen unique intact mAb Mw values were identified by
441
charge envelope deconvolution and theoretical Mw prediction. The results showed that this
21
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
442
methodology offered a real alternative for the structural interrogation of mAb charge heterogeneity
443
from the currently used methods based on fractionation and following LC–MS analysis. In addition,
444
the stainless steel sprayer is robust and easy to install, potentially providing a worry free
445
environment for cIEF-MS operation.
446 447
5. Acknowledgment
448 449
The study was supported by Nanjing Normal University, National Natural Science Foundation of
450
China (Grant Number 21475061), and Natural Sciences and Engineering Research Council of
451
Canada (NSERC). LW acknowledges a Mitacs Accelerate Fellowship sponsored by PromoChrom
452
(Richmond, BC). The access to Agilent CE−MS instrumentation and the infliximab formulation
453
were kindly provided by Agilent Technologies, Beijing, China.
454 455
6. References
456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476
(1) Jorgenson, J. W.; Lukacs, K. D. Anal. Chem. 1981, 53, 1298-1302. (2) Hjerten, S. J. Chromatogr. A 1985, 346, 265-270. (3) Rodriguez-Diaz, R.; Wehr, T.; Zhu, M. D. Electrophoresis 1997, 18, 2134-2144. (4) Olivares, J. A.; Nguyen, N. T.; Yonker, C. R.; Smith, R. D. Anal. Chem. 1987, 59, 1230-1232. (5) Smith, R. D.; Wahl, J. H.; Goodlett, D. R.; Hofstadler, S. A. Anal. Chem. 1993, 65, 574A-584A. (6) Maxwell, E. J.; Chen, D. D. Y. Anal. Chim. Acta 2008, 627, 25-33. (7) Kleparnik, K. Electrophoresis 2015, 36, 159-178. (8) Yates, J. R. Nat. Methods 2011, 8, 633-637. (9) Zubarev, R. A.; Makarov, A. Anal. Chem. 2013, 85, 5288-5296. (10) Cheng, Y. F.; Dovichi, N. J. Science 1988, 242, 562-564. (11) Sun, L.; Zhu, G.; Zhao, Y.; Yan, X.; Mou, S.; Dovichi, N. J. Angew. Chem. Int. Ed. 2013, 52, 13661-13664. (12) Moini, M. Anal. Chem. 2007, 79, 4241-4246. (13) Faserl, K.; Sarg, B.; Kremser, L.; Lindner, H. Anal. Chem. 2011, 83, 7297-7305. (14) Redman, E. A.; Batz, N. G.; Mellors, J. S.; Ramsey, J. M. Anal. Chem. 2015, 87, 2264-2272. (15) Maxwell, E. J.; Zhong, X.; Zhang, H.; van Zeijl, N.; Chen, D. D. Electrophoresis 2010, 31, 1130-1137. (16) Maxwell, E. J.; Zhong, X.; Chen, D. D. Anal. Chem. 2010, 82, 8377-8381. (17) Zhong, X.; Maxwell, E. J.; Chen, D. D. Anal. Chem. 2011, 83, 4916-4923. (18) Tang, Q.; Harrata, A. K.; Lee, C. S. Anal. Chem. 1995, 67, 3515-3519.
22
ACS Paragon Plus Environment
Page 22 of 24
Page 23 of 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510
Analytical Chemistry
(19) Huhner, J.; Lammerhofer, M.; Neususs, C. Electrophoresis 2015, 36, 2670-2686. (20) Zhong, X.; Maxwell, E. J.; Ratnayake, C.; Mack, S.; Chen, D. D. Anal. Chem. 2011, 83, 87488755. (21) Dai, J.; Lamp, J.; Xia, Q. W.; Zhang, Y. R. Anal. Chem. 2018, 90, 2246-2254. (22) Zhu, G.; Sun, L.; Keithley, R. B.; Dovichi, N. J. Anal. Chem. 2013, 85, 7221-7229. (23) Sun, L.; Zhu, G.; Dovichi, N. J. Anal. Chem. 2013, 85, 4187-4194. (24) Zhu, G.; Sun, L.; Dovichi, N. J. J. Sep. Sci. 2017, 40, 948-953. (25) Yang, L.; Lee, C. S.; Hofstadler, S. A.; Pasa-Tolic, L.; Smith, R. D. Anal. Chem. 1998, 70, 3235-3241. (26) Jensen, P. K.; Pasa-Tolic, L.; Anderson, G. A.; Horner, J. A.; Lipton, M. S.; Bruce, J. E.; Smith, R. D. Anal. Chem. 1999, 71, 2076-2084. (27) Kuroda, Y.; Yukinaga, H.; Kitano, M.; Noguchi, T.; Nemati, M.; Shibukawa, A.; Nakagawa, T.; Matsuzaki, K. J. Pharm. Biomed. Anal. 2005, 37, 423-428. (28) Mokaddem, M.; Gareil, P.; Varenne, A. Electrophoresis 2009, 30, 4040-4048. (29) Lecoeur, M.; Gareil, P.; Varenne, A. J. Chromatogr. A 2010, 1217, 7293-7301. (30) Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Br. J. Pharmacol. 2009, 157, 220-233. (31) Weiner, L. M.; Surana, R.; Wang, S. Z. Nat. Rev. Immunol. 2010, 10, 317-327. (32) Gaughan, C. L. Mol. Divers. 2016, 20, 255-270. (33) Liu, H.; Ponniah, G.; Zhang, H. M.; Nowak, C.; Neill, A.; Gonzalez-Lopez, N.; Patel, R.; Cheng, G.; Kita, A. Z.; Andrien, B. mAbs 2014, 6, 1145-1154. (34) Liu, H.; Gaza-Bulseco, G.; Faldu, D.; Chumsae, C.; Sun, J. J. Pharm. Sci. 2008, 97, 2426-2447. (35) Hosken, B. D.; Li, C.; Mullappally, B.; Co, C.; Zhang, B. Anal. Chem. 2016, 88, 5662-5669. (36) Beck, A.; Wagner-Rousset, E.; Ayoub, D.; Van Dorsselaer, A.; Sanglier-Cianférani, S. Anal. Chem. 2013, 85, 715-736. (37) Shen, Y. F.; Smith, R. D. J. Microcolumn Sep. 2000, 12, 135-141. (38) Dada, O. O.; Ramsay, L. M.; Dickerson, J. A.; Cermak, N.; Jiang, R.; Zhu, C.; Dovichi, N. J. Anal. Bioanal. Chem. 2010, 397, 3305-3310. (39) Righetti, P. G. Isoelectric focusing: theory, methodology and application; Elsevier, 2000; Vol. 11. (40) Antes, B.; Amon, S.; Rizzi, A.; Wiederkum, S.; Kainer, M.; Szolar, O.; Fido, M.; Kircheis, R.; Nechansky, A. J. Chromatogr. B 2007, 852, 250-256. (41) Huang, L.; Lu, J.; Wroblewski, V. J.; Beals, J. M.; Riggin, R. M. Anal. Chem. 2005, 77, 14321439.
511
23
ACS Paragon Plus Environment
Analytical Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
512
For TOC Only
513
24
ACS Paragon Plus Environment
Page 24 of 24